



Press Release

FOR IMMEDIATE RELEASE

Cellzome Appoints Dr. David Brown as President and CEO

HEIDELBERG, Germany, September 16, 2002

Cellzome AG today announced that it has appointed David Brown, Ph.D., to the position of President and Chief Executive Officer. Dr. Brown, 52, succeeds Charles Cohen, Ph.D., who will now serve as Chairman of the company's Supervisory Board. Most recently, Dr. Brown served as Global Head of Discovery at Roche Pharma in Basel, Switzerland, overseeing the output of drug candidates from approximately 2,000 scientists across Roche's five research sites.

"David's expertise will be critical in the continued evolution of Cellzome into an integrated product-oriented company," said Dr. Cohen. "Cellzome's objective is to develop better drugs by improving the efficiency of the discovery process through connecting data pertaining to biochemical pathways, the biology responsible for disease onset and progression and the basic mode of action of drugs. We have succeeded in developing strong technological resources and we are now focused on applying them to develop drugs in certain therapeutic categories. His leadership and know-how in discovery and development will take Cellzome to a new level."

Dr. Brown has extensive experience in leading research and development initiatives from its early discovery phase through clinical trial process in major disease areas. Over his 28-year career, he has worked at four of the top 10 pharmaceutical companies, including Roche Pharma, Pfizer Inc., GlaxoWellcome and Zeneca. At Roche, in addition to his role of leading discovery, Dr. Brown served on a committee overseeing the company's clinical drug development and was also a member of the business development team responsible for licensing products and for finalizing technology agreements and acquisitions. While at Pfizer, Dr. Brown was a co-inventor on the patent for Viagra® and led the team that developed the blockbuster drug through to clinical efficacy in man.

For further information please contact:

Cellzome AG

David Brown, Ph.D., President and CEO
Tel: +49-62 21-137 57-0
info@cellzome.com

Noonan Russo/Presence Euro RSCG

Wendy Lau (USA)
Tel: +1-212-845-4272
w.lau@nrp-euro.com

"I am pleased to join and lead Cellzome which I believe has a very powerful approach to drug discovery that will play a key role in developing the next generation of medicines for patients in need," said Dr. Brown. "Cellzome has world-leading functional proteomics capabilities and I am particularly excited to come in at this time when its programs are advancing at such a rapid pace."

Cellzome has established a technology platform that identifies connections between proteins in a cell. Its pharmaco-wiring approach is being used to reveal novel drug targets, identify potential new medical uses for currently marketed drugs and leads currently in development, offer insight into the development of effective combination drug therapies and that also provide a mechanistic explanation for secondary drug effects and toxicity. The company's programs are focused on central nervous system disorders, inflammation, metabolic disorders and oncology.

About Cellzome AG

Cellzome AG is a biopharmaceutical company with laboratories and operations in Heidelberg, Germany and Elstree, England, just north of London. The company is involved in drug discovery and development through the use of proprietary functional proteomics technologies. Cellzome's primary areas of therapeutic focus include neurology, oncology, metabolic disorders and diseases where inflammation plays a central role. Cellzome's platform enables better understanding of the mode of action of existing and potential drugs, creating the opportunity to develop second-generation drugs with higher efficacy, specificity and safety profile. The company was founded in May 2000 with a team of scientists from the European Molecular Biology Laboratory (EMBL), including pioneers in the fields of protein mass spectrometry, bioinformatics, structural biology and the biology and biochemistry of signal transduction. The company currently has 120 employees. Learn more at www.cellzome.com.